Implications of TP53 Allelic State for Genome Stability, Clinical Presentation and Outcomes in Myelodysplastic Syndromes
Elsa Bernard, Yasuhito Nannya, Robert Paul Hasserjian, Sean M. Devlin, Heinz Tuechler, Juan Santiago Medina-Martinez, Tetsuichi Yoshizato, Yusuke Shiozawa, Ryunosuke Saiki, Luca Malcovati, Max Fine Levine, Juan E. Arango, Yangyu Zhou, Francesc Gessé Solé, Catherine A. Cargo, , Elli Papaemmanuil
The paper examines TP53 allelic states in MDS patients, finding that bi-allelic targeting is linked to worse outcomes, while mono-allelic targeting does not differ from wild-type patients.
Nature Medicine · Aug 3, 2020Peer-reviewedGenomics